This is a demo store. No orders will be fulfilled.

LV-320

    级别和纯度:
  • ≥95%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
L648052-5mg
5mg 期货 Stock Image
L648052-10mg
10mg 期货 Stock Image
L648052-50mg
50mg 期货 Stock Image

基本描述

规格或纯度 ≥95%
英文名称 LV-320
生化机理 LV-320 是一种强效、非竞争性 ATG4B 抑制剂,其 IC 50 为 24.5u2009µM,K d 为 16u2009µM。LV-320 可抑制 ATG4B 酶的活性,阻断细胞中的自噬通量,并且稳定、无毒,在体内具有活性。
储存温度 -20°C储存
运输条件 超低温冰袋运输
产品介绍


LV-320 is a potent and uncompetitive ATG4B inhibitor with an IC 50 of 24.5 µM and a K d of 16 µM. LV-320 inhibits ATG4B enzymatic activity, blocks autophagic flux in cells, and is stable, non-toxic and active in vivo

In Vitro

LV-320 (0-120 µM; SKBR3, MCF7, JIMT1, and MDA-MB-231 cells) treatment results in a dose-dependent increase in endogenous LC3B-II and protein p62 levels in all four cell lines. LV-320 (120 µM; 48 hours; MDA-MB-231 cells) treatment results in an increase in LC3B-II, indicating that LV-320 blocks autophagic flux. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: SKBR3, MCF7, JIMT1, and MDA-MB-231 cells Concentration: 0 µM, 25 µM, 50 µM, 75 µM, 100 µM, or 120 µM Incubation Time: Result: Resulted in a dose-dependent increase in endogenous LC3B-II and protein p62 levels in all four cell lines. Cell Autophagy AssayCell Line: MDA-MB-231 cells Concentration: 120 µM Incubation Time: 48 hours Result: Blocked autophagic flux.

In Vivo

LV-320 (100-200 mg/kg; oral gavage; three times over two days; GFP-LC3 mice) treatment results in a terminal blood level of 169 µM and a liver level of 104 µM. The expression of GFP-LC3 puncta is significantly greater accumulation in LV-320 treated animals compared to controls. LC3B-II protein is also increased in LV-320-treated animals. The treatment do not cause significant toxicity in mice at either dose . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: GFP-LC3 mice (females, 9-14 weeks) Dosage: 100 mg/kg or 200 mg/kg Administration: Oral gavage; three times over two days (Pharmacokinetic study) Result: Terminal blood levels were 169 µM and liver levels were 104 µM. LC3B-II protein level was also increased.

Form:Solid

IC50& Target:IC50: 24.5 µM (ATG4B),Kd: 16 μM (ATG4B)

纯度 ≥95%

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

名称和识别符

分子类型 未知
IIUPAC Name 3-[[4-[(E)-2-(7-chloroquinolin-4-yl)ethenyl]phenyl]-(2-phenylethylsulfanyl)methyl]sulfanylpropanoic acid
INCHI 1S/C29H26ClNO2S2/c30-25-12-13-26-23(14-17-31-27(26)20-25)9-6-22-7-10-24(11-8-22)29(35-19-16-28(32)33)34-18-15-21-4-2-1-3-5-21/h1-14,17,20,29H,15-16,18-19H2,(H,32,33)/b9-6+
InChi Key PHENTWJNXGESKT-RMKNXTFCSA-N
Smiles C1=CC=C(C=C1)CCSC(C2=CC=C(C=C2)C=CC3=C4C=CC(=CC4=NC=C3)Cl)SCCC(=O)O
Isomeric SMILES C1=CC=C(C=C1)CCSC(C2=CC=C(C=C2)/C=C/C3=C4C=CC(=CC4=NC=C3)Cl)SCCC(=O)O
PubChem CID 134817239
分子量 520.11

化学和物理性质

溶解性 DMSO : 135 mg/mL (259.56 mM; Need ultrasonic)

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

溶液计算器